NC-SYNTERACT
4.2.2020 13:02:08 CET | Business Wire | Press release
Synteract , an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition extends Synteract’s existing global footprint into Asia Pacific and Africa, and offers another core biometrics services hub, complementary to those it operates in Europe and the U.S.
Clindata , with offices in Bloemfontein, South Africa, and Colombo, Sri Lanka, is a biometrics Clinical Research Organization, offering biostatistics, programming and data management services across all phases of drug development. Clindata’s Veterinary division will continue to operate under the Clindata name, independently from Synteract, while the Human Health Biometrics division will combine with Synteract. The combination of Clindata’s experienced team of biometrics professionals with that of Synteract’s further enhances Synteract’s biometrics capabilities as part of its integrated, full-service program; dedicated FSP solution , or as a standalone biometrics service to augment clients’ in-house capabilities.
“Like Synteract, Clindata is known for high quality service delivery, collaboration, agility and expertise of its teams,” says Synteract CEO Steve Powell . “Innovative changes in biometrics are transforming the ways in which clinical study data is collected, integrated and analyzed. Rich patient data gives researchers insights into disease progression and response to therapy in ways we have not seen before. This is an exciting time to be adding even more expertise to our teams and will allow us to deliver global biometrics services covering every time-zone.”
With a wealth of data management, CDISC, biostatistics and SAS experience, the Clindata team have significant experience running Phase I-IV studies across the complementary therapeutic areas of Synteract. Clindata CEO, Theo Erasmus, adds, “With our combined biometrics capabilities, clients will benefit from a complete service offering incorporating all data components from research, advice on study design, document planning to PK analyses and results interpretation, as well as global capabilities, all provided by one integrated CRO. We are glad to be joining Synteract and creating a world class delivery team.”
Synteract is a portfolio company of Amulet Capital Partners, LP. Financial terms are not being disclosed.
About Synteract
“Bringing Clinical Trials to Life ” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development with multi-disciplinary teams and deep expertise. Synteract has conducted nearly 4,000 studies on six continents and has contributed to more than 240 product approvals. Synteract offers notable depth of expertise in oncology, dermatology, general medicine, neuroscience, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter .
About Clindata
Founded in 2012, Clindata is a Contract Research Organization (CRO) based in South Africa. The Clindata core team of experienced, dedicated staff has worked for in the CRO and health industry for many years. We bring a wealth of Data Management, CDISC, Biostatistics and SAS experience. Our team members have significant experience gained from working on studies of various phases and throughout an array of therapeutic areas.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rehlko Defines What It Takes to Build AI-Ready Power Infrastructure as Data Center Energy Demands Evolve4.8.2026 15:15:00 CEST | Press release
New eBook highlights how increasingly dynamic AI workloads are reshaping critical power requirements and explores strategies for building resilient, scalable energy infrastructure Rehlko, a global industrial energy resilience platform providing custom-engineered, integrated power solutions for mission-critical infrastructure worldwide, today released new insights on the power infrastructure requirements emerging from the rapid growth of large language models and artificial intelligence. In its latest eBook, AI Readiness Starts with Power: Designing for Real-World Load Conditions, Rehlko examines how increasingly dynamic AI workloads are reshaping expectations for data center power systems and highlights key infrastructure considerations for operators seeking to scale AI capacity reliably and efficiently. As the eBook outlines, AI readiness is increasingly defined not by installed capacity, but by how systems perform under highly variable real-world load conditions. The AI Power Challen
HappyRobot Raises $150 Million Series C to Build Enterprise Superintelligence4.8.2026 14:30:00 CEST | Press release
New funding led by Prysm Capital and co-led by Eurazeo will accelerate global growth as HappyRobot expands its engineering, deployment and go-to-market teams HappyRobot, the company putting AI agents to work across complex enterprise operations, today announced it has raised $150 million in Series C funding led by Prysm Capital and co-led by Eurazeo. Existing investors a16z, Base10, Y Combinator are doubling down with participation from strategics like Koch Disruptive Technologies (KDT), Orange, and T.Capital (Deutsche Telekom), Bankinter, Endeavor Catalyst, Kfund and Wave-X. The round values the company at $1.2 billion post-money, bringing total funding to around $200 million and marking a new stage of growth as enterprises deploy AI agents across mission-critical work. HappyRobot works with more than 150+ enterprise customers, including DHL, Kuehne + Nagel, Naturgy, Repsol, and Uber, and has grown 5x since raising its Series B late last year. After first proving its platform in logis
New 3D Flash Memory Technology from Kioxia and Sandisk Achieves Industry’s Highest Bit Density for QLC NAND4.8.2026 14:30:00 CEST | Press release
10th-generation QLC 3D flash memory represents a major leap forward for AI storage architectures, cloud platforms, and data‑intensive innovations Future of Memory and Storage Conference (FMS) – Kioxia Corporation, a subsidiary of Kioxia Holdings Corporation (TOKYO: 285A) and Sandisk Corporation (Nasdaq: SNDK) today unveiled their next-generation Quad-Level-Cell (QLC) 3D flash memory technology, which delivers up to 60% increase in bit density compared to their 8th-generation, surpassing 37 Gb/mm² and setting the industry benchmark1 for bit density, performance and power efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804147821/en/ Leveraging the companies’ revolutionary CMOS directly Bonded to Array (CBA) technology2 which fabricates CMOS logic and the memory array on separate wafers before bonding them together with high-precision wafer-to-wafer alignment, the new generation improves read and write bandwidth c
Altasciences Completes Expansion of Research and Development Laboratory in Harleysville, Pennsylvania4.8.2026 14:00:00 CEST | Press release
Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804164599/en/ From left to right: Nasir Egal (General Manager, CDMO Services); Marie-Hélène Raigneau (Chief Executive Officer); Anuji Abraham (Senior Director, Pharmaceutical Development, CDMO Services); Robert Sabelli (Co-Chief Operating Officer); Cathy Konidas (Chief Administrative Officer) The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scientific disciplines. “With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities t
Vasion® is Imprivata®-Ready Certified to Bring Trusted Identity Across Healthcare Print Infrastructure4.8.2026 14:00:00 CEST | Press release
New integration brings Imprivata Enterprise Access Management directly into the Vasion Platform: closing the identity gap at the print layer, enabling clinicians and healthcare users to securely release jobs at any printer with a single badge tap. Vasion, a leader in intelligent print automation, today announced a strategic integration with Imprivata, a leading digital identity and access management company for life- and mission-critical industries, starting with healthcare. The Vasion platform, with PrinterLogic®, PrinterLogic Output, and Vasion Automate, offers shared Imprivata customers a unified identity layer, spanning endpoints and printers, for secure, enterprise-wide visibility into every print job. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804404337/en/ The integration is designed to maximize existing Imprivata deployments. No rip-and-replace is required. The Vasion platform works with the Imprivata infrastr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom